Transgene Biotek narrows September-quarter loss to Rs 34.53 lakh

Transgene Biotek Limited reported a standalone loss of Rs 34.53 lakh for the quarter ended 30 September 2026, narrowing from Rs 38.84 lakh a year earlier, while revenue from operations increased to Rs 6 lakh from Rs 5.28 lakh. Finance costs of Rs 28.95 lakh remained above quarterly operating revenue.

How did Transgene Biotek perform in the September quarter?

Transgene Biotek’s standalone loss narrowed by Rs 4.31 lakh year on year to Rs 34.53 lakh in the September 2026 quarter. Revenue from operations rose by Rs 0.72 lakh to Rs 6 lakh, while total income was also Rs 6 lakh because the company reported no other income. There were no exceptional items and no tax expense, so the reported loss before tax and loss for the period were both Rs 34.53 lakh.

The sequential comparison also showed a smaller loss. The June 2026 quarter recorded a loss of Rs 38.90 lakh, compared with Rs 34.53 lakh in the September quarter, as total expenses declined to Rs 40.53 lakh from Rs 44.90 lakh. Revenue was unchanged at Rs 6 lakh across the two quarters. Basic and diluted loss per equity share were each Rs 0.05 in September 2026, unchanged from both June 2026 and September 2025.

What drove the change in Transgene Biotek’s expenses?

Transgene Biotek reduced total standalone expenses by Rs 3.59 lakh from the September 2025 quarter, more than the Rs 0.72 lakh rise in revenue. Other expenses fell to Rs 4.07 lakh from Rs 9.40 lakh, while depreciation and amortisation declined to Rs 4.13 lakh from Rs 4.98 lakh. Employee benefit expense increased slightly to Rs 3.38 lakh from Rs 3.31 lakh.

Finance cost remained the largest reported expense at Rs 28.95 lakh, rising by Rs 2.52 lakh from Rs 26.43 lakh a year earlier and remaining unchanged from June 2026. It accounted for about 71% of September-quarter total expenses of Rs 40.53 lakh, based on the disclosed figures, and was nearly five times revenue of Rs 6 lakh. Other expenses declined by Rs 4.38 lakh sequentially from Rs 8.45 lakh; the note for the period ended 30 September 2026 lists legal and professional charges of Rs 2.63 lakh within this category.

For the six months ended 30 September 2026, revenue rose to Rs 12 lakh from Rs 10.23 lakh in the corresponding prior-year period. Total expenses fell to Rs 85.43 lakh from Rs 92.44 lakh, producing a loss of Rs 73.43 lakh, compared with Rs 82.21 lakh a year earlier. Finance costs nevertheless increased to Rs 57.90 lakh from Rs 50.98 lakh over the same six-month comparison.

What does Transgene Biotek’s balance sheet show?

Transgene Biotek reported standalone total assets of Rs 33.7131 crore at 30 September 2026, marginally lower than Rs 33.7647 crore at 31 March 2026. Non-current assets were Rs 32.6636 crore, including loans of Rs 23.0204 crore, other intangible assets of Rs 4.6667 crore and property, plant and equipment of Rs 3.014 crore. Current assets were Rs 1.0495 crore, up from Rs 1.0184 crore at the March year-end.

Standalone equity remained negative at Rs 9.9341 crore at 30 September 2026, compared with negative Rs 9.1998 crore at 31 March 2026. Equity share capital was unchanged at Rs 75.77 crore, while other equity widened to negative Rs 85.7041 crore from negative Rs 84.9698 crore, consistent with the Rs 73.43 lakh loss for the six months. The balance sheet recorded non-current borrowings of Rs 7.2171 crore and current borrowings of Rs 10.5731 crore, together amounting to Rs 17.7902 crore.

Cash and cash equivalents were Rs 5.32 lakh at 30 September 2026 and bank balances other than cash equivalents were Rs 1.08 lakh. The cash-flow statement reported Rs 7.13 lakh of net cash used in operating activities and Rs 7.45 lakh generated from financing activities for the period ended 30 September 2026. Borrowing proceeds were Rs 65.35 lakh and finance costs were Rs 57.90 lakh; the statement reported cash and cash equivalents of Rs 6.40 lakh at period end.

What legal matters and corporate events does Transgene Biotek disclose?

Transgene Biotek disclosed several unresolved proceedings alongside its 30 September 2026 results. The Appellate Tribunal, Enforcement Directorate, New Delhi matter was adjourned from 2 November 2026 to 12 January 2027. The company also said the Securities Appellate Tribunal matter had hearings on 23 September, 16 October and 29 October 2026 but had not reached finality.

The filing states that BIRAC had filed a petition at the National Company Law Tribunal, Hyderabad Bench, claiming outstanding interest, with notice served on 5 November 2026, and management said it had taken steps to defend the matter. Transgene Biotek also disclosed its appeal in the Bombay High Court Commercial Division against an 8 July 2026 order directing payment of Rs 92.9925 lakh plus interest at 6% a year on the principal amount; it said it was awaiting commencement of the hearing.

The company said the National Company Law Tribunal, Hyderabad dismissed a petition by Babaji Netralayya Pvt Ltd on 5 November 2026. However, management said it was responding to a 6 November 2026 notice concerning the possible imposition of a penalty under Section 65 of the Code. Separately, the board approved the reappointment of Dr. K. Koteswara Rao as Chairman and Managing Director for one year from 13 November 2026, subject to shareholder approval at the 36th annual general meeting on 30 December 2026.

Conclusion

Transgene Biotek’s September-quarter result showed a narrower loss, supported by lower total and other expenses, while operating revenue rose modestly to Rs 6 lakh. The six-month comparison followed the same direction, with loss narrowing by Rs 8.78 lakh to Rs 73.43 lakh. However, quarterly finance costs of Rs 28.95 lakh continued to exceed revenue, and standalone equity was negative Rs 9.9341 crore at 30 September 2026.

The next disclosed event is the 36th annual general meeting scheduled for 30 December 2026 at 11:00 a.m. Indian Standard Time through video conferencing or other audio-visual means, where the proposed one-year reappointment of Dr. K. Koteswara Rao is subject to shareholder approval. Investors can also watch the 12 January 2027 hearing date in the Enforcement Directorate appellate matter, as well as developments in the BIRAC and Section 65 National Company Law Tribunal matters.